8-K: 180 Life Sciences Receives Notice of Allowance for U.S. Patent Covering Method to Prevent Post-Operative Cognitive Dysfunction

180 Life Sciences Corp. announces the receipt of a Notice of Allowance for a U.S. patent covering a novel method to prevent or reduce post-operative cognitive dysfunction.

Summary

• 180 Life Sciences Corp. has received a Notice of Allowance from the USPTO for a U.S. patent application No. 17/556,584.
• The patent covers a novel method for preventing or reducing Post-Operative Cognitive Dysfunction (POCD).
• The Notice of Allowance indicates that the USPTO has determined the application meets all requirements for patentability.
• The company cautions that a final patent grant cannot yet be assured.
• The allowed patent covers a method for reducing POCD, particularly delirium, by administering an anti-Human tumor necrosis factor (TNF) Alpha ('ATNF') monoclonal antibody before and during surgery.
• 180 Life Sciences is also advancing its strategic pivot toward acquiring and developing online casino and related entertainment businesses through its proprietary Technology Gaming Platform.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the patent allowance, but tempered by the risks associated with the company's strategic pivot and potential need for further financing.

Positives

• The Notice of Allowance signifies that the USPTO has determined that the application meets all requirements for patentability.
• The patent, if issued, will enhance the value of the company's biotechnology portfolio by protecting a novel therapeutic approach to an area of significant unmet medical need.
• The company is actively pursuing a strategic pivot into the iGaming sector, potentially diversifying its revenue streams.

Negatives

• The company cautions that a final patent grant cannot yet be assured.
• The company is pivoting away from biotechnology and into the iGaming sector, which may not be viewed positively by all investors.

Risks

• The final patent grant is not assured.
• The company's ability to raise funding to support its operations and commercialize its Gaming Technology Platform is a risk.
• The terms of any further financing may be highly dilutive and may include onerous terms.
• The company's lack of experience with operating a gaming company is a risk.
• The company's ability to build out or acquire a front end for the Gaming Technology Platform is a risk.
• The company's ability to generate revenue from the Gaming Technology Platform is a risk.
• Competition in the iGaming industry is a risk.
• Risks relating to fraud, theft or cheating exist.
• The company's ability to obtain and maintain licenses, and the terms thereof, is a risk.
• The company's required reliance on third party cloud service providers and providers of third-party communications infrastructure, hardware and software is a risk.
• Potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have violated the intellectual property of others is a risk.
• Global economic conditions, geopolitical events and regulatory changes are risks.
• The effect of changing interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts are risks.

Future Outlook

The company plans to continue maximizing the value of its existing biotechnology portfolio while advancing its strategic pivot toward acquiring and developing online casino and related entertainment businesses through its proprietary Technology Gaming Platform.

Management Comments

• Blair Jordan, Chief Executive Officer of 180 Life Sciences, stated that the Notice of Allowance highlights the underlying value of their legacy biotechnology assets and reflects the strength of intellectual property that continues to underpin 180 Life Sciences.
• Blair Jordan also stated that the company remains committed to maximizing the value of its existing biotechnology portfolio as they build their future in the dynamic global iGaming sector.
• Blair Jordan also stated that the Notice of Allowance for a US Patent demonstrates the ongoing value that our legacy IP portfolio has, and also shows that the Company is continuing to enhance this value for the benefit of all stockholders.

Industry Context

The announcement comes as 180 Life Sciences is pivoting towards the iGaming sector, indicating a strategic shift from its legacy biotechnology focus. The patent allowance provides a potential value-add to its existing IP portfolio as it enters a new industry.

Comparison to Industry Standards

• It's difficult to compare this announcement to industry standards without knowing the specific details of the ATNF therapy and its efficacy compared to existing treatments for POCD.
• However, the company mentions that there are few effective preventive treatments available, suggesting a potential competitive advantage if the patent leads to a successful product.
• In the iGaming sector, the company will be competing with established players like Flutter Entertainment, Entain, and DraftKings, requiring significant investment and execution to gain market share.

Stakeholder Impact

• Shareholders may benefit from the potential value enhancement of the biotechnology portfolio and the strategic pivot into the iGaming sector.
• Patients may benefit from the development of a new treatment for POCD.
• Employees may be affected by the strategic shift in the company's focus.

Next Steps

• Completion of final administrative procedures for the patent issuance.
• Advancing the strategic pivot toward acquiring and developing online casino and related entertainment businesses.
• Commercializing the Gaming Technology Platform.

Key Dates

Keywords

patent, POCD, iGaming, ATNF, biotechnology, 180 Life Sciences, Notice of Allowance